81 96
Funding/Support
and
role
of
the
sponsor:
None.
Acknowledgment
statement:
We
thank
the
following members
of
the
bladder
cancer
research
consortium:
Margit
Fisch,
Robert
S.
Svatek,
Lukas Lusuardi, Anirban Mitra, Siamak Daneshmand, Yair Lotan, Douglas
S.
Scherr, Marek
Babjuk,
and Debasish
Sundi.
References
[1]
Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663–76.
[2]
Bochner BH, Kattan MW, Vora KC. Postoperative nomogram pre- dicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967–72.[3]
Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transi- tional cell carcinoma of the bladder. J Urol 2006;176:1354–61, discussion 1361–2.
[4]
Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle- invasive and metastatic bladder cancer: update of the EAU guide- lines. Eur Urol 2011;59:1009–18.
[5]
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75.[6]
Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a con- temporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414–22, discussion 2422.[7]
Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystec- tomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690–6.
[8]
Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors pre- dicting outcome of therapy. J Clin Oncol 1999;17:3173–81.
[9]
Rink M, Lee DJ, Kent M, et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 2013; 111:E30–6.[10]
Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post- recurrence survival in bladder cancer following radical cystectomy. BJU Int 2012;109:846–54.[11]
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.[12]
Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48.
[13]
Apolo AB, Ostrovnaya I, Halabi S, et al. Prognostic model for predict- ing survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 2013;105: 499–503.[14]
Berod AA, Colin P, Yates DR, et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int 2012;110:E1035–40.[15]
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: devel- opment and validation. J Chronic Dis 1987;40:373–83.
[16]
Morgan TM, Tang D, Stratton KL, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923–8.[17]
Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307: 1941–51.
[18]
Nakagawa T, Hara T, Kawahara T, et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recur- rence after radical cystectomy. J Urol 2013;189:1275–81.[19]
Rink M, Sjoberg D, Comploj E, et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 2012;19:4337–44.
[20]
Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and ade- quacy, and measuring and reducing errors. Stat Med 1996;15: 361–87.[21]
Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/ cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30:1107–13.[22]
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer ‘‘unfit’’ for cisplatin-based chemotherapy: phase II–results of EORTC study 30986. J Clin Oncol 2009;27:5634–9.[23]
Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013;189: 1214–21.
[24]
Ripamonti CI, Farina G, Garassino MC. Predictive models in pallia- tive care. Cancer 2009;115(Suppl):3128–34.
[25]
Galsky MD, Moshier E, Krege S, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013;119:3012–9.[26]
Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850–5.
[27]
Mayr R, May M, Martini T, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662–70.
E U R O P E A N
U R O L O G Y
F O C U S
1
( 2 0 1 5
)
7 5 – 8 1
81